Severe congenital neutropenia due to G6PC3 deficiency: early and delayed phenotype in two patients with two novel mutations by unknown
ITALIAN JOURNAL
OF PEDIATRICS
Notarangelo et al. Italian Journal of Pediatrics 2014, 40:80
http://www.ijponline.net/content/40/1/80CASE REPORT Open AccessSevere congenital neutropenia due to G6PC3
deficiency: early and delayed phenotype in two
patients with two novel mutations
Lucia Dora Notarangelo1*, Gianfranco Savoldi2, Sara Cavagnini1, Veronica Bennato1, Sabrina Vasile3, Alba Pilotta4,
Alessandro Plebani5 and Fulvio Porta1Abstract
Severe Congenital Neutropenia type 4 (SCN4, OMIM 612541) is a rare autosomal recessive disease due to mutations
in the G6PC3 gene. The phenotype comprises neutropenia of variable severity and other anomalies including
congenital heart defects, prominent superficial veins, uro-genital anomalies, facial dysmorphism, growth and
developmental delay and intermittent thrombocytopenia. In some patients, SCN represents the only manifestation of
the disease. Variable findings have been reported at bone marrow examination ranging from a maturation arrest at the
myelocyte/promyelocyte stage (either in a hypocellular or hypercellular context) to myelokathexis. Here we report two
patients harbouring two novel mutations in the G6PC3 gene, including the first Italian patient even described. Both the
patients share profound neutropenia with severe infections early in life; in one case non-hematopoietic stigmata of the
syndrome, including evident facial dysmorphism and vascular anomalies, appeared gradually over time, prominently in
the second decade. Therefore, G6PC3 defects should be considered in any case of congenital, unexplained neutropenia
regardless of the clinical phenotype. Both patients are on G-CSF treatment with no evidence of malignant evolution.
Even if G6PC3 deficiency seems not to have a propensity towards malignancy, a careful evaluation is warranted.
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Severe congenital neutropenia (SCN) is a heterogeneous
group of mature neutrophil deficiency disorders with or
without immunological or extra-hematopoietic abnor-
malities [1]. Various genetic defects can cause SCN, and
some of them also predispose to MDS/AML [2]. SCN
type 4 (SCN4, OMIM 612541) is a rare autosomal recessive
disease due to mutations in the G6PC3 gene which encodes
for the catalytic subunit of the glucose-6-phosphatase 3
protein (G6Pase3) [3]. Along with G-6Pase, which is
mutated in Glycogen Storage Disease Type 1 (GSD1),
G-6Pase 3 belongs to the glucose-6-phosphatase (Glc-
6-Pase) family, a group of transmembrane, endoplasmic
reticulum (ER)- associated proteins [3]. Although the
two isoenzymes share the same catalytic properties, only* Correspondence: luciadora.notarangelo@spedalicivili.brescia.it
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article, unless otherwise stated.defects in G-6Pase are associated with metabolic symptoms,
reflecting their unique role in fasting glucose homeostasis
and different tissue expression patterns [3].
The human G6PC3 gene is located at chromosome
17q21 and has 6 exons. SNC4 is most often due to
missense mutations. Moreover, some mutations occur
with higher frequency in certain ethnic groups, possibly
reflecting a founder effect [4,5]. Since the first descrip-
tion, 59 patients with SCN4 have been reported. All of
them share neutropenia of variable severity and some
have other anomalies including congenital heart defects,
prominent superficial veins, uro-genital anomalies, facial
dysmorphism, growth and developmental delay and
intermittent thrombocytopenia [4,6]. In some patients,
SCN represents the only manifestation of the disease [7].
Mutation of the same gene may give rise to Dursun
Sindrome (DS) (OMIM 613034), a more severe, often
lethal, phenotype [8]. This syndrome is characterizedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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(PPH), leucopenia and atrial septal defects [9]. Other
features include secundum-type atrial septal defect,
intermittent neutropenia, lymphopenia, monocytosis,
anemia, and thymic hypoplasia. The prognosis is often
poor due to severe respiratory distress [9]. Here we re-
port two patients harbouring two novel mutations in
G6PC3 gene, including the first Italian patient who is
also, to our knowledge, the longest survivor with SCN4
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Patient 1
The proband is a 20 year old female, second child of
healthy and unrelated Italian parents, born at term after
an uneventful pregnancy. She developed recurrent and
serious S. aureus infections since early in life (skin infec-
tion at 10 days of age, pulmonary abscess at 2 months,
brain abscess leading to lateralized seizures at 5 months)
(Table 1). Complete blood cell count showed normal
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Figure 1 Segregation analysis of the mutations identified in
patient 1 (A) and patient 2 (B).
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(Hb 8.6 g/dl, MCV 78 fl) and thrombocytosis (610 × 109/L).
Immunological evaluation, including serum immunoglobu-
lins, lymphocyte subsets, expression of adhesion molecules,
complement, dihydrorhodamine (DHR) test, was nor-
mal (Table 1). Due to persistent neutropenia, a bone
marrow aspiration was performed, which showed global
hypercellularity with myeloid hyperplasia, maturation
arrest at the promyelocyte-myelocyte stage and paucity
of mature neutrophils. Treatment with G-CSF was
started (5–10 μg/Kg/d) with normalization of ANC
(>1,500 cell/μl). At 8 yrs of age, the patient developed
thrombocytopenia (33 × 109/L), which was initially at-
tributed to G-CSF treatment. Subsequently the platelet
count spontaneously increased with an intermittent course
(Table 1). Reduced height growth speed was observed
since 10 years of age. Because of delayed puberty, a deca-
peptyl test was performed at 16 years, and results were
consistent with hypergonadotrophic hypogonadism (data
not shown). A facial dysmorphism with frontal bossing,
upturned nose and retrognatia became more evident over
time, prominently in the second decade, along with the
appearance of edema and superficial venous pattern of the
lower limbs around 13 years. Other non hematological as-
pects are reported in Table 1. Upon informed consent, the
coding region of the G6PC3 gene was sequenced, reveal-
ing compound heterozygosity for c.144C >A substitution
(predicted to result in p.Y48* premature termination) and
a novel three nucleotide deletion (c.373_375delAAT),
predicted to cause deletion of the Isoleucine residue at
position 125 (p.I125del). Each parent was found to be
heterozygous for one of the two mutations (see Figure 1A).
In order to define the pathogenic role of the variants
identified in our patients, we performed DHPLC ana-
lysis on 150 samples of genomic DNA (300 chromo-
somes) from unrelated healthy control individuals [10].
Analysis by DHPLC of the PCR fragments containing
the mutations did not show any alterations of the
DHPLC profiles in the control subjects analysed. The
patient is currently 20 years old without major infec-
tions or developmental delay, on G-CSF treatment
(2 μg/Kg/d). Yearly bone marrow evaluations have
confirmed previous findings.
Patient 2
A male patient, third child of consanguineous Turkish
parents, was referred to us at the age of 2 years for severe
neutropenia and early-onset recurrent infections including
otitis, parotitis, S. viridans sepsis, S. aureus gluteal abscess,
and recurrent aphtous stomatitis (Table 1). Mild sensori-
neural hearing loss was diagnosed at 4 months of life. At
6 months of age, the patient developed chickenpox without
complications. Bone marrow aspiration, performed at an-
other institution, revealed delayed granulocyte maturation.No mutations were found in the ELANE and HAX1 genes.
On physical examination, the weight was 13 Kg (25-50th
percentile), and length was 88 cm (50th percentile). There
was facial dysmorphism with frontal bossing, upturned
nose and malar hypoplasia, prominent superficial venous
pattern on the arms, legs and trunk, and micropenis
with coronal ipospadia. Laboratory investigations re-
vealed severe neutropenia (ANC: 140 cells/μL) with nor-
mal lymphocyte, monocyte and platelet counts, slight
microcytic anemia (Hb 10,5 g/dl; MCV 65,4 fl), normal
serum immunoglobulins, protective antibody response to
tetanus toxoid, and normal distribution of lymphocyte
subsets. Abdominal ultrasound and echocardiography
were also normal (see Table 1). Upon informed consent,
mutation analysis of the G6PC3 gene was performed
and revealed a novel homozygous 5 bp indel mutation
(c.680_684delinsT) in exon 6, resulting in Serine to
Leucine substitution at position 227, and frameshift with
Notarangelo et al. Italian Journal of Pediatrics 2014, 40:80 Page 4 of 6
http://www.ijponline.net/content/40/1/80premature termination (p.S227Lfs*3). Both parents were
found heterozygous for the mutation (see Figure 1B).
DHPLC analysis on 150 samples of genomic DNA (300
chromosomes) from unrelated healthy control individuals
didn’t show any alterations [10]. Treatment with G-CSF
(5 μg/Kg/d) was started with rapid increase of ANC (12,200
cells/μL). Due to the appearance of thrombocytopenia
(71 × 109/L) and splenomegaly, treatment with G-CSF was
suspended with clinical and laboratory resolution and
then re-started at the dose of 4 μg/Kg 3 times/week. At
present, the patient is 3 years old, infection-free and his
ANC is stably around 2,000 cells/μL. Other than mild
and transient splenomegaly, no adverse events have
been observed.
Discussion
Biallelic mutations in the G6PC3 gene are associated
with a variable phenotype. In the two largest series re-
ported until now [4,11] severe neutropenia predisposing
to severe infections is the most reliable marker of dis-
ease, since congenital heart defects (mostly atrial septal
defects) are present in around 80% of patients while
prominent superficial veins and facial dysmorphism are
frequent but less consistent. Furthermore, six patients
with G6PC3 mutations associated with non syndromic
SCN have been described [7]. The role of G6PC3 muta-
tions in causing non hematological manifestations of
SCN4 is not yet clear. Neutrophils and skin fibroblasts
from SCN4 patients have an increased susceptibility to
apoptosis through a mechanism that involves glycogen
synthetase kinase 3 beta (GSK-3beta) and endoplasmic
reticulum stress. The same mechanism also may play a
role in causing dysmorphism [12]. Variable findings have
been reported at bone marrow examination: most patients
present a maturation arrest at the myelocyte/promyelocyte
stage (either in a hypocellurar or hypercellular context),
however myelokathexis has been also observed [13]. No
genotype-phenotype correlation has been demonstrated
to explaine the bone marrow variability as the same
mutation can cause either maturation arrest or normo/
hypercellular bone marrow [14]. On the contrary, the
extra-hematological aspects of the syndrome could be
possibly related to the variation in the residual activity
of the enzyme, as well as to the genetic or environmen-
tal background, since specific missense mutations has
been found in association with non-syndromic patients
[4,7]. It has been postulated that missense mutations
with a higher residual activity could predispose to a
non -syndromic phenotype [7]. We herein report on
two new cases of SCN4. In addition to contributing two
novel G6PC3 mutations, the patients described also
offer some diagnostic and therapeutic observations. Pa-
tient 1 illustrates that non-hematopoietic stigmata of
the syndrome (including evident facial dysmorphismand vascular anomalies) may appear gradually over
time, making the diagnosis difficult early in life. The six
patients with non syndromic SCN4 reported were all in
the first and second decade of life, the oldest one being
18 years old [7]. Longer follow up studies are needed to
assess whether SCN4 is uniformly associated with extra-
hematopoietic manifestations (which may also occur later
in life) or whether in some patients the clinical phenotype
may be restricted to SCN for the entire duration of life.
Therefore, G6PC3 mutation analysis should be consid-
ered in all cases of congenital, unexplained neutropenia,
regardless of the presence of extra-hematopoietic mani-
festations or of parental consanguinity, once ELANE
and HAX1 mutations are ruled out.
Growth retardation and delayed puberty have been
reported in some patients with SCN4 [15]. In one case,
hypogonadotrophic hypogonadism was documented, and
hypothyroidism was considered an extra-hematological
manifestation of SCN4 in another patient [15,16]. Re-
cently, testicular failure with very high levels of luteinizing
hormone (LH) and follicle-stimulating hormone (FSH)
has been reported in a G6PC3 subject [17]. Patient 1 in
this report showed delayed puberty with appearance of ir-
regular menses at 17 years of life. Results of the decapeptyl
test were consistent with hypergonadotrophic hypogonad-
ism, and additional tests demonstrated normal estrogen
levels and increased LH values, as in partial ovarian in-
sufficiency. The observation of hormonal and growth
abnormalities in several patients suggest that appropri-
ate endocrine evaluation should be considered in SCN4
patients.
Sensorineural hearing loss has been previously re-
ported in five patients, all of which were homozygous
for a G6PC3 mutation; moreover parental consanguinity
was documented or postulated in several of them [4].
Patient 2 in this report also suffered from sensorineural
deafness. Given the relatively high frequency of genetic-
ally determined sensorineural deafness in the general
population, it remains to be determined whether the lat-
ter represents a novel syndromic aspect of the disease,
or whether parental consanguinity may have caused sim-
ultaneous inheritance of distinct, autosomal recessive
genetic defects in G6PC3 and in another gene respon-
sible for sensorineural deafness.
The G6PC3 protein is a paralog of G6PC with which it
shares 36% sequence identity [3]. Since the G6PC3 pro-
tein structure is not well defined, the functional conse-
quences of the mutations are predicted based on studies
performed on the better known G6PC protein. The
I125del mutation in patient 1 is located in the trans-
membrane region and may interfere with the correct
folding and stability, in analogy with the effect of mis-
sense, transmembrane mutations in the G6PC protein
[4]. Patient 2 presents a new complex mutation in exon
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inal domain with a premature stop codon after three
amino acids. Although no functional studies have been
performed to investigate the consequences of this muta-
tion, the occurrence of a premature termination likely
interferes with both the structure and the function of
the protein.
Recombinant human G-CSF has been successfully
employed in the treatment of congenital neutropenia
since the end of 80’s , with reduction of the rate of se-
vere infections and improved quality of life, even if some
short and long-term adverse effects have been reported
[18,19]. Thrombocytopenia and splenomegaly are fre-
quent complications of G-CSF treatment. In patient 1
thrombocytopenia was at first attributed to G-CSF therapy;
however, its intermittent course, not related to changes of
G-CSF dosage, is similar to what is reported in 10% of
G6PC3 patients, and is therefore most likely related to the
disease itself [11]. In patient 2, both splenomegaly and
thrombocytopenia were possibly due to the G-CSF treat-
ment, since they regressed after treatment discontinuation,
with subsequent reappearence of a mild splenomegaly even
at lower doses of G-CSF.
Leukemic transformation is well documented in pa-
tients with SCN on G-CSF treatment. Factors contribut-
ing to leukemic transformation include the genetic type
and severity of neutropenia and G-CSF exposure, i.e.
cumulative dose as well as mean dose per injection [20].
Interestingly, no cases of leukemia have been reported in
patients with SCN4, possibly due to the young age and
the small size of the cohort described [11]. Patient 1 in
this report has been treated with G-CSF continuously
for 20 years, at a median dose of 3.9 μg/Kg/day (range
2.2-5), with no evidence of leukemia or myelodysplasia
on repeated examinations of bone marrow specimens.
Nevertheless, a careful evaluation of a possible malignant
evolution is warranted.Consent
Written informed consent was obtained from the patients
for pubblication of this Case report and any accompanying
images. A copy of the written consent is available for
review by the Editor-in-Chief of this journal.
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